Trial Profile
A phase 1 first-in-human, randomized, double–blind, placebo-controlled dose escalation trial of a single intravenous dose of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers - HDIT101-01
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2019
Price :
$35
*
At a glance
- Drugs HDIT-101 (Primary)
- Indications Herpes simplex virus infections
- Focus Adverse reactions; First in man
- Acronyms HDIT101-01
- Sponsors Heidelberg ImmunoTherapeutics
- 14 Jan 2019 Status changed from recruiting to completed.
- 27 Jun 2018 New trial record